Clinical Trials Medical Aspect Ratio 1200 384

Our AML Clinical Trials

Vor Bio is currently conducting two clinical trials for AML.

VBP101 Clinical Trial

The VBP101 trial, a Phase 1/2a study of trem-cel (VOR33) in combination with Mylotarg™, is actively enrolling patients. This clinical trial will evaluate trem-cel in patients with AML undergoing an allogeneic hematopoietic cell transplant (HCT).

VBP301 Clinical Trial

The VBP301 trial studying VCAR33ALLO, a donor-derived CD33-directed CAR-T cell therapy, is actively enrolling patients. VCAR33ALLO is being studied in the VBP301 clinical trial, which focuses on patients who have relapsed following allogeneic stem cell transplant, including patients who have previously received trem‑cel.

If you have questions, please contact us.

The science behind the Vor Bio platform

We are applying proven technologies in new ways by genetically modifying healthy donor HSCs for protection and enabling use of modalities such as ADCs and CAR-Ts post-transplant.